The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
Open accessAbstract
Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma. Widespread use has been limited for several reasons, including concern that their use may preclude enrollment in subsequent clinical trials due to uncertainty about confounding of results and potential toxicities. This meta-analysis estimated survival following treatment with CW for HGG. A literature search identified relevant studies. Overall survival (OS), median survival, and adverse events (AEs) were summarized. Analysis of variance evaluated effects of treatment (CW vs non-CW) and diagnosis (new vs recurrent) on median survival. The analysis included 62 publications, which reported data for 60 studies (CW: n = 3,162; non-CW: n = 1,736). For newly-diagnosed HGG, 1-year OS was 67 % with CW and 48 % without; 2-year OS was 26 and 15 %, respectively; median survival was 16.4 ± 21.6 months and 13.1 ± 29.9 months, respectively. For recurrent HGG, 1-year OS was 37 % with CW and 34 % without; 2-year OS was 15 and 12 %, respectively; median survival was 9.7 ± 20.9 months and 8.6 ± 22.6 months, respectively. Effects of treatment (longer median survival with CW than without; P = 0.043) and diagnosis (longer median survival for newly-diagnosed HGG than recurrent; P < 0.001) on median survival were significant, with no significant treatment-by-diagnosis interaction (P = 0.620). The most common AE associated with wafer removal was surgical site infection (SSI); the most common AEs for repeat surgery were mass effect, SSI, hydrocephalus, cysts in resection cavity, acute hematoma, wound healing complications, and brain necrosis. These data may be useful in the context of utilizing CW in HGG management, and in designing future clinical trials to allow CW-treated patients to participate in experimental protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gilbert, M. R., Dignam, J., Won, M., Blumenthal, D. T., Vogelbaum, M. A., Aldape, K. D., Colman, H., Chakravarti, A., Jeraj, R., Armstrong, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.1 · Cited by 70
Cited by
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050
Drug delivery by supramolecular design
Webber, M. J., & Langer, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00391a · Cited by 814
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
Weil, S., Osswald, M., Solecki, G., Grosch, J., Jung, E., Lemke, D., Ratliff, M., Hänggi, D., Wick, W., & Winkler, F. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox070 · Cited by 317
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Metadata
- Authors
- Chowdhary, S. A., Ryken, T., & Newton, H. B.
- Venue
- Journal of Neuro-Oncology
- Published
- 2015-01-29
- Volume
- 122
- Issue
- 2
- Pages
- 367-382
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W1974000574
- Cited by
- 167
- References
- 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. https://app.cochat.ai/papers/10.1007/s11060-015-1724-2
- The paper
- Chowdhary, S. A., Ryken, T., & Newton, H. B. (2015). Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-015-1724-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.